STAT+: Pharma’s reputation with patient groups dips again, mostly due to pricing issues
For the second consecutive year, the pharma industry saw its reputation dip among patient advocacy groups, largely due to ongoing concerns over pricing issues.
For the second consecutive year, the pharmaceutical industry saw its reputation slip among patient advocacy groups, largely due to ongoing concerns over pricing issues, according to a new survey.
Of more than 2,500 groups queried, 56% reported the industry had an “excellent” or “good” reputation as it goes about the business of developing and providing medicines. Although the findings suggest a clear majority were mostly satisfied with drug companies, this marked a second consecutive annual decline — albeit, a slight one — after several years in which the industry was seen more positively.
The previous survey found that 57% of the groups indicated the industry had an “excellent” or “good” reputation. The back-to-back declines come after 60% of patient groups believed the industry fared well thanks to the initial response of many companies to quickly develop salves for the Covid-19 pandemic. In 2021, for instance, 59% of companies scored highly, compared with 41% in 2018.
